medigraphic.com

2015, Number 1

<< Back Next >>

Rev Hematol Mex 2015; 16 (1)

Frequency and varieties of lymphomas in a Mexican public hospital

Cruz-Contreras D, Reyes-Pérez EN, Limón-Flores A, Mendoza-García A, Gutiérrez-Quiróz C, Pérez-Corro M, Castillo-Canto C, Díaz-Martínez D

Language: Spanish
References: 23
Page: 9-16
PDF size: 392.95 Kb.


ABSTRACT

Background: The lymphomas are lymphocytic malignant neoplasms. There are two subtypes: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The most frequent NHL subtype is diffuse large B cell lymphoma (DLBCL), and the most frequent HL subtype is nodular sclerosis.
Objective: To know the frequency of the distinct varieties of lymphoma in Mexican patients assisting to a third level hospital.
Material and method: A descriptive and retrospective study was done with the records of Pathology Service of Hospital de Especialidades, IMSS, Puebla, were reviewed from January 2013 to November 2014. All cases of lymphomas with immunostains and classified according to World Health Organization (WHO) 2008 were selected. They were divided in HL and NHL and their subtypes.
Results: We found 240 lymphoma cases, 8 were excluded because they were not classified according to WHO 2008 criteria, thus, we included 232 cases. Two-hundred five (88%) cases were NHL and 27 (12%) were HL. The most frequent NHL variant was DLBCL with 105 (51%) cases, in second place it was extranodal marginal zone lymphoma MALT type with 21 cases (10%) and in third place it was follicular type with 19 cases (9%). The most frequent HL variant was classic HL with 26 cases (96%), then nodular lymphocyte predominance HL with 1 case (4%). The most frequent classic HL variant was mixed cellularity with 12 cases (46%) and in second place nodular sclerosis with 10 cases (38%).
Conclusions: In contrast with worldwide literature, in our Center the second most frequent NHL variant was extranodal marginal zone lymphoma MALT instead of follicular type.


REFERENCES

  1. Novelli S, Briones J, Sierra J. Epidemiology of lymphoid malignancies: last decade update. Springerplus 2013;2:70-74.

  2. Word Z, Matasar M. Advances in the diagnosis and management of lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 2012;2:29-55.

  3. Boffeta P. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol 2011;22:27-31.

  4. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011;117:1792-1798.

  5. Morton LM, Slager SL, Cerhan JR, Wang S, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;48:130-44.

  6. Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics, 2011 The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.

  7. Townsend W, Linch D. Hodgkin’s lymphoma in adults. Lancet 2012;380:836-847.

  8. Sitio oficial del Centro de Investigación del cáncer Reino Unido 2011: http://www.cancerresearchuk.org/cancerinfo/ cancerstats/types/hodgkinslymphoma/incidence/uk-hodgkins- lymphoma-incidence-statistics. Consulta 09-12-2014.

  9. Hochberg J, Waxman I, Kelly K. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Hematol 2008;144:24-40.

  10. Bluhm E, Ronckers C, Hayashi R, Neglia J, et al. Causespecific mortality and second cancer incidence after non- Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2008;111:4014-4021.

  11. Beyar O, Barak A, Abrahami G. Treatment of T cell lymphoblastic lymphoma in children and adolescents: Israel Society of Pediatric Hematology Oncology Retrospective Study. Isr Med Assoc J 2011;13:161-165.

  12. Reiter A. Diagnosis and treatment of childhood non- Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:285-296.

  13. Dinand V. Current strategies in the management of pediatric Hodgkin’s lymphoma. Indian J Med Paediatr Oncol 2008;29:27-38.

  14. Guerra-Soto A, Rebolloso-Zuñiga E, González-Sánchez A, Rubio-Jurado B, Nava A. Linfoma no Hodgkin: conceptos generales. El Residente 2013;8:23-34.

  15. Labardini J, Cervera E, Corrales C, Balbuena M y col. Oncoguía: linfoma no Hodgkin. Cancerología 2011;6:139-152.

  16. Labardini J, Cervera E, Corrales C, M, Barbosa A y col. Oncoguía: Linfoma de Hodgkin. Cancerología 2011;6:133-138.

  17. Olaya VA, Arias R, Rivera LR. Linfoma de Hodgkin en individuos menores de 10 años de edad. Experiencia del Instituto Nacional de Pediatría. Tesis. Universidad Nacional Autónoma de México. México, DF. 2000.

  18. Fajardo A, Mejía J, Hernández L, et al. Epidemiología descriptiva de las neoplasias malignas en niños. Rev Panam Salud Pública 1999;6:75-88.

  19. Secretaría de Salud de México. Perfil epidemiológico del cáncer en niños y adolescentes en México. 2011;30-35.

  20. Sitio oficial del Instituto Nacional del Cáncer 2014. http:// www.cancer.gov/espanol/tipos/nohodgkin. Consulta 03-01-2015.

  21. Kraus A, Ruiz-Argüelles JG, De León O, Pérez R. Estudios sobre linfomas. Rev Invest Clin Mex 1980;32:179-186.

  22. Torres J, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998;178:1089-1094.

  23. Ruiz-Argüelles GJ, Mercado Díaz MA, Ponce-de-León S, Ponce-de-León S, Pérez-Tamayo R. Studies on lymphomata III. Lymphomata, granulomata and tuberculosis. Cancer 1983;52:258-262.




2020     |     www.medigraphic.com